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Abstract
Background: We aimed at constructing Lactococcus lactis strains expressing HPV-16 recombinant E7 (rE7) oncoprotein
and examining its overproduction ability followed by optimizing batch and fed-batch fermentations. Thereafter, in
order to assess the immunogenicity of recombinant L. lactis cells, C57BL/6 mice were immunized by oral gavage.
Results: The results suggested that recombinant strains harboring optiE7 and E7 genes produced a maximum of 4.84
and 1.91 μg/mL of rE7 in static flask experiments, while the corresponding strains gave a maximum yield of 35.49 and
14.24 μg/mL in batch experiments, respectively. Fed-batch study indicated that the concentration of rE7 protein
significantly increased after feeding yeast extract plus GM17 medium. The rE7 production of the best performing
strains was 2.09- and 1.48-fold higher than that of the strains during the batch fermentation. Furthermore, biomass
levels were 1.98- and 1.92-fold higher than those in batch cultivation. Oral immunization of C57BL/6 mice with
recombinant L. lactis produced significant specific IgG and IgA antibody responses in serum and vaginal fluids,
respectively. Our outcomes suggest that vaccination with L. lactis expressing rE7 can generate significant protective
effects against E7-expressing cell line. Also, our study provides evidence that the presence of large amounts of E7-
specific CD4+ T helper and CD8+ T cell precursors was stimulated. Significantly higher frequencies of HPV-16 E7 specific
IL-2- and IFN-γ-secreting T cells were detected in antigen-stimulated splenocytes and intestinal mucosal lymphocytes,
when compared to the control groups.
Conclusions: We conclude that optimization of culture conditions along with recombinant protein expression can
highly stimulate both specific humoral and cell-mediated immune responses in mice after oral immunization. These
promising results represent a step towards fast-tracking a vaccine against HPV-16-associated cervical cancer.
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Background
Human papillomavirus (HPV) infection represents the
most important risk factor for developing cervical cancer
which is the second cause of cancer-related deaths in
women worldwide [1–3]. Human papillomavirus types
16 and 18 cause 60–70% of cervical cancer worldwide,
with other HPV types causing virtually all the remaining
cases [4]. Transformation of proteins E6 and E7 of
human papillomaviruses are consistently expressed in
HPV-associated cervical cancers and are required for
maintenance of the transformed state [5]. Therefore, E6
and E7 could be more effective candidates as potential
tumor-specific targets for T cell-based immunotherapy
of cervical cancer [6, 7].
Several studies have examined the use of bacteria
(such as Salmonella and Mycobacterium spp) as E7 anti-
gen delivery vehicles to elicit an immune response
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against HPV-16 [8]. Unfortunately, these organisms
could recover their pathogenic potential and are not to-
tally safe for use in humans, especially in older people,
children, and immunosuppressed patients [9]. However,
lactic acid bacteria (LAB) are promising candidates for
in vivo delivery of antigens because of their long and
safe association with humans and their food. These dairy
microorganisms have been used for centuries in the
fermentation and preservation of numerous foods and
are considered to be safe microorganisms with a GRAS
(Generally Recognized As Safe) status [10, 11]. Lactococ-
cus lactis (a model lactic acid bacterium) has several
advantages over other well-known protein producers.
For example, this bacterium does not produce LPS or
any proteases, its genome has been completely se-
quenced, and it is easy to manipulate genetically [12].
Further, many protein expression- and targeting-systems
have already been developed for L. lactis for the intra- or
extra-cellular production of numerous proteins of viral,
bacterial, or eukaryotic origins [13, 14]. In addition, oral
administration with genetic engineered L. lactis has proved
to elicit both systemic and mucosal immunity [8, 15].
To create large amounts of cells, the genetically modi-
fied bacteria or yeast are grown in large fermentation
vessels containing all the nutrients they need [6, 16].
Also, in order to produce a protein of interest in fermen-
ters, secretion is generally preferred to cytoplasmic pro-
duction as it allows continuous culture and simplifies
purification [17].
In the present study, we constructed an expression
vector containing native and codon optimized HPV-16
E7 gene isolated from Iranian patients. Afterwards, we
explored the valuable power of statistical experimental
design to optimize the production of recombinant E7
during batch and fed-batch experiments. The yields of
rE7 production and biomass for both strains were deter-
mined before and after optimization. To study the ex-
pression and immunogenicity of the cloned genes in
recombinant L. lactis, C57BL/6 mice were orally immu-
nized with the live recombinants, where fresh sera and
vaginal secretion were used to determine IgG and IgA
antibody titers. Also, spleen and intestinal cells were




Various physiological and chemical properties of the target
protein were assessed by ProtParam tool. These included
formula: C854H1372N222O268S12, total number of atoms:
2728, theoretical pI: 4.78, grand average of hydropathicity
(GRAVY): -0.057, total number of negatively charged resi-
dues (Asp + Glu): 26, total number of positively charged
residues (Arg + Lys): 16, aliphatic index score: 95.97, and
instability index (II) score: 49.97.
According to SignalP 4.1, we obtained a discrimination
score (D-score) of 0.640 at the position of 27–28 amino
acid residues, which was above the default cut-off point
of 0.450, suggesting that there is a signal peptide at the
N-terminus of recombinant HPV-16 E7 protein (Fig. 1a).
The Swiss modeling server was employed to build the
tertiary structure of pNZ8123-SPUsp45-HPV16E7. The
structure of C-terminal E73-K124 residues of Ld30b pro-
tein was obtained using the template PDB-2f8b (NMR
structure of the C-terminal domain (dimer) of HPV-45
oncoprotein E7) as E7 protein displayed homology (in
pairwise protein alignment) at NA resolution, sequence
identity~ 46.00%, similarity ~ 43%, with the QMEAN
score of − 1.87. The intricate spatial architecture of
HPV-16 E7 indicated that there were 13 (7.38) α-helices
and 10 (5.68%) β-sheets in the three-dimensional structure
of pNZ8123-SPUsp45-HPV16E7 (Fig. 1b).
Western blotting and ELISA analysis of the recombinant
E7 protein
Western blot analysis was employed to test the relative
level of expression of the codon optimized HPV-16 E7
and Native HPV-16 E7. Induced NZ9000 strains con-
taining pNZ8123-HPV16-optiE7 showed an abundance
of recombinant E7 protein in the supernatant fraction.
The protein band migrated to about 18 kDa which is
clearly visible in the Western blot analysis (Fig. 1c, right
panel). The Induced NZ9000 strain containing
pNZ8123-HPV16-E7 revealed a low level of the recom-
binant E7 protein in the supernatant, with the protein
band migrating to about 18 kDa in the Western blot
analysis (Fig. 1c, left panel). These results suggest that
the codon optimization might synergistically improve
expression of rE7 protein.
Not surprisingly, the rE7 production and biomass
increased steeply with elevation of nisin concentration
beyond 10 (optiE7) and 5 (E7) ng/mL during the
optimization process, though the optimal level was
significantly different between L. lactis strains. Accord-
ingly, maximum expression levels of L. lactis harboring
optiE7 (2.19 μg/mL) and E7 (1 μg/mL) were obtained at
final concentrations of 15 (optiE7) and 10 ng/mL (E7), at
30 °C, 5 and 4 h following induction remaining after 8 h
(Fig. 2a).
We also found that the optimal nisin concentration
coupled with lower-temperature culture conditions
(from 30° to 20° C) resulted in increased ability of pro-
duction of rE7 proteins in L. lactis harboring optiE7
(4.67 μg/mL) and E7 (1.86 μg/mL) with induction
times of 7 and 6 h, respectively (Fig. 2b). However, we
observed a small but consistent decline in dry weight
levels in the strains.
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It was observed that induction at the optical density
OD600 = 0.6 (optiE7) and 0.7 (E7) led to high production
of the recombinant rE7 protein by L. lactis having optiE7
(4.84 μg/mL) and E7 (1.91 μg/mL), respectively at 20 °C
(Fig. 2c).
Optimization study of batch fermentation
In order to investigate the production of biomass and rE7
during the course of batch fermentation, both cells (L.
lactis carrying pNZ8123-HPV16-optiE7 and pNZ8123-
HPV16-E7) were induced with 15 and 10 ng/mL nisin at
OD600 = 0.6 and 0.7, respectively. The growth was rapid,
and the major part of the glucose was consumed within
about 7 h after induction. The results indicated that when
L. lactis cells were cultured in the presence of 25 g/L
glucose, the cell growth, glucose utilization, and lactic acid
production were significantly reduced in both strains.
Similarity, the cultures grew far more slowly at high initial
glucose concentrations (100 g/L), since the cells were
unable to utilize all the glucose. So, rE7 expression seemed
to diminish more significantly after 35–40 h. At 50 g/L of
glucose, the highest biomass concentration and maximum
rE7 protein yields in fermenters achieved by NZ9000
containing pNZ8123-HPV16-optiE7 were 4.95 g/L and
35.49 μg/mL at around 30 h. Also, at glucose 75 g/L, the
corresponding values achieved by NZ9000 containing
pNZ8123-HPV16-E7 were 1.56 g/L and 14.24 μg/mL, at
around 30 h. Also, the final yields of rE7 proteins using L.
lactis harboring pNZ8123-HPV16-optiE7 (35.2836–
35.6631 with 95% CI) were close to a maximum, of 2.49
times (P < 0.0001) greater than those of the L. lactis har-
boring pNZ8123-HPV16-E7 vector (13.6794–14.7739 with
95% CI) (Fig. 3 (left), panel A). Further, L. lactis harboring
pNZ8123-HPV16-optiE7 (4.7232–5.0101 with 95% CI)
showed a higher biomass production (3.12-fold) compared
with L. lactis containing pNZ8123-HPV16-E7 (1.5455–
1.6945 with 95% CI) (Fig. 3 (left), panel B).
The results indicated that the maximum values of rE7
(extracellular form) concentrations were achieved by the
end of the fermentation, while being still considerably
higher compared to our previous batch production of
intracellular rE7 oncoprotein (1.8916–2.6350 with 95% CI
of difference, P = 0.0001 for E7 and, 1.9321–2.4746 with
95% CI of difference, P < 0.0001 for optiE7). Further, the
Fig. 1 Panel a: The amino acid sequence of HPV-16 E7 containing SPusp45 signal peptide obtained from pNZ8123 vector was subjected to
SignalP 4.1 analysis. SignalP graphical output represents the three different scores including raw cleavage site score (C-score) which is trained to
distinguish signal peptide cleavage site; signal peptide score (S-score) which is trained to locate the signal peptides of a protein; and combination of
C-score and the slope of S-score (Y- score). Furthermore, discrimination score (D-score) characterized the mean S and maximum Y scores, utilized for
discriminating the signal peptide from its non-signal counterpart. Panel b: The protein tertiary structure of HPV-16 E7; the three-dimensional structure
was established using SWISS-MODEL (http://swissmodel.expasy.org/). There were 13 α-helices and 10 β-sheets in the three-dimensional structure of
HPV-16 E7. Panel c: Western blot analysis of rE7 proteins produced in L. lactis harboring pNZ8123-HPV16-optiE7 (right panel), prestained protein ladder
(center panel), and pNZ8123-HPV16-E7 (left panel)
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maximum values for the biomass were higher than the
levels reached in the previous batch study (−
0.007348–0.1540 with 95% CI of difference, P = 0.0651
for DCW of E7, and, − 0.1537- 0.2937 with 95% CI of
difference, P = 0.4339 for DCW of optiE7) [12].
Optimization study of fed-batch fermentation
The fed-batch culture was initiated following overnight
batch culture with initial glucose concentrations of 50
and 75 g/L.
In the first fed-batch fermentation, the production of
rE7 started at the beginning of the exponential growth
phase and reached a maximum of about 68.22 and
17.83 μg/mL in this phase (for L. lactis containing
pNZ8123-HPV16-optiE7 and pNZ8123-HPV16-E7, re-
spectively). Accordingly, the highest maximum cell growth
(8 and 2.49 g/L) was obtained after 30 h of fermentation.
The maximal viable cell number was 5 × 109 and 1 × 109
CFU/mL, which decreased gradually upon lengthening the
fermentation. Indeed, the E7 and optiE7 levels obtained at
the end of this fed-batch culture were only 1.25 (3.1407–
3.9193 with 95% CI of difference, P < 0.0001) and 1.92
(32.1766–33.5767 with 95% CI of difference, P < 0.0001)
times higher than those obtained in the batch fermentation.
Fig. 2 Influence of rising nisin levels and temperature 30 °C (panel a), growing nisin levels and temperature 20 °C (panel b), and induction at OD600
(panel c) at various time points on the expression of rE7 proteins in L. lactis containing pNZ8123-HPV16-optiE7 (Left) and pNZ8123-HPV16-E7 (right).
Panel a and b: Induction time with 1 ng/mL (diamond), 5 ng/mL (square), 10 ng/mL (triangles), 15 ng/mL (multiple), and 20 ng/mL (star) nisin. Panel
c (at 20 °C): induction at OD600 = 0.5 (diamond), OD600 = 0.6 (square), OD600 = 0.7 (triangle), OD600 = 0.8 (multiple)
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At the end of the exponential growth phase of
fed-batch fermentation 2, the yields of rE7 proteins were
about 74.32 and 21.19 μg/mL, respectively. The max-
imum biomass concentrations were 9.83 and 3 g/L, and
the maximal viable cell numbers were 7.2 × 109 and
3.5 × 109 CFU/mL, respectively. The results obtained in-
dicated that the feeding with yeast extract increased both
the E7 and optiE7 expression by 1.18 times (range, 3.0181
to 4.4752 with 95% CI of difference, P = 0.0001) and 1.08
times (range, 5.0295 to 6.7771 with 95% CI of difference, P
< 0.0001) when compared to the fed-batch fermentation 1.
In the third fed-batch experiment, the expression
obtained in the exponential growth phase increased to
the maximal production (70.38 and 19.55 μg/mL), and
then the rE7 secretion decreased dramatically. The max-
imum biomass concentrations were 9.12 and 2.81 g/L
when glucose was completely consumed. The maximal
viable cell number was 4 × 109 and 1.5 × 109 CFU/mL. In
this fermentation, high concentrations of glucose were
able to reduce pH within a shorter time when compared
to fed-batch fermentations 2. However, after 40 h of
incubation, the obtained expression of E7 and optiE7
was 1.09-fold (− 8.8023–13.1123 with 95% CI of differ-
ence, P = 0.6560) and 1.05-fold (− 28.2592–50.2552 with
95% CI of difference, P = 0.5289) lower than the concen-
tration achieved in the fed-batch fermentation 2. Overall,
western blot results clearly demonstrate that rE7 pro-
duction as well as biomass was significantly higher
Fig. 3 Protein expression (panel a) and biomass production (panel b), profile of L. lactis containing pNZ8123-HPV16-optiE7 (square) and pNZ8123-
HPV16-E7 (diamond) during the course of batch (left) and fed-batch (right) fermentation; Panel c: Western blotting detection of rE7 proteins
expressed in L. lactis carrying pNZ8123-HPV16-optiE7 (lane native, N) and pNZ8123-HPV16-optiE7 (lane optimized, O) during the batch (left) and
fed batch (right) fermentation
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during the fed-batch culture of L. lactis harboring
pNZ8123-HPV16-optiE7 compared to the batch studies
(Fig. 3, panel C).
Antibody, cytokine, and CTL responses following oral
immunizations
To evaluate the humoral immune responses in sera, the
sera were collected from all vaccinated mice on days 1,
14, 29, and 41. We examined the antibody responses in
this experiment in relevant groups: PBS, LLEV, LLE7BF,
LLE7FBF, LLOE7BF, and LLOE7FBF using indirect-
ELISA. There was no significant serum IgG detected in
the PBS and LLEV groups during the entire day (P =
0.7634). The production of HPV-16 E7 specific IgG in
the LLE7BF, LLE7FBF, LLOE7BF, and LLOE7FBF groups
was enhanced (P < 0.0001), suggesting that the recom-
binant constructs expressing rE7 activated the immune
response. Nevertheless, LLE7FBF and LLOE7FBF mice
groups could elicit a higher significant specific IgG titer
compared to the PBS or LLEV group on days 1, 14, 29,
and 41 (P < 0.0001) (Fig. 4 (left), panel A).
To assess whether recombinant L. lactis expressing
rE7 could induce mucosal immune responses, vaginal
washes were collected on days 1, 14, 29, 41. There was
no significant SIgA produced across the groups on day 1
(P = 0.9372). Compared to control groups (PBS or
LLEV), oral vaccination in mice could significantly elicit
the SIgA antibody responses (P < 0.0001). On the other
hand, LLE7FBF and LLOE7FBF groups induced signifi-
cantly higher detectable levels of specific SIgA compared
to PBS or LLEV group on days 14, 29, and 41 in the
vaginal washes (P < 0.0001) (Fig. 4 (right), panel A).
To evaluate the amount of cytokines produced upon
vaccination with recombinant L. lactis expressing rE7,
the splenocytes and intestinal mucosal lymphocytes from
immunized mice were taken and stimulated with MHC
class I - restricted peptides (HPV-16 E749–57) and MHC
class II - restricted peptides (HPV-16 E730–67). Under
equal counts of L. lactis harboring pNZ8123-HPV16-
optiE7 and pNZ8123-HPV16-E7, compared with PBS
and LLEV groups, immunization of LLE7FBF and
LLOE7FBF mice groups stimulated more cytokines (P
< 0.0001), containing IFN-γ and IL-2, when compared
to immunization of LLE7BF and LLOE7BF on day 41
(P < 0.0001) (Fig. 4b and c).
In comparison with LLE7BF_CD4 and LLOE7BF_CD4
groups, LLE7FBF_CD4 and LLOE7FBF_CD4 groups pro-
voked nearly 1.77 time (111.9185 to 121.4815 vs. 59.9774
to 71.8226 spot-forming cells (SFC) per 104 cells with 95%
CI of difference, P < 0.0001) and 1.34 time (128.0828 to
141.3172 vs. 94.9395 to 105.8605 spot-forming cells (SFC)
per 104 cells with 95% CI of difference, P < 0.0001) as
much IL-2 in splenocytes respectively (Fig. 4 (left), panel
B), and nearly 1.68 time (125.3837 to 132.8163 vs. 70.5602
to 82.4398 spot-forming cells (SFC) per 104 cells) and 1.31
time (157.3700 to 166.4300 vs. 117.6951 to 129.1049
spot-forming cells (SFC) per 104 cells) respectively as
much IL-2 in the intestinal mucosal lymphocytes (Fig. 4
(right), panel B). Also, in comparison with LLE7BF_CD8
and LLOE7BF_CD8 groups, LLE7FBF_CD8 and
LLOE7FBF_CD8 groups provoked nearly 1.75 time
(75.6792 to 91.1208 vs. 41.0177 to 53.7823 spot-forming
cells (SFC) per 104 cells with 95% CI of difference, P <
0.0001) and 1.32 time (89.6951 to 101.1049 vs. 67.6820 to
76.1180 spot-forming cells (SFC) per 104 cells with 95%
CI of difference, P < 0.0001) as much IL-2 in splenocytes
respectively Fig. 4 (left), panel B), and nearly 1.71 time
(95.2645 to 107.1355 vs. 55.1608 to 63.0392 spot-forming
cells (SFC) per 104 cells) and 1.21 time (112.7805 to
120.0195 vs. 90.1335 to 100.8665 spot-forming cells (SFC)
per 104 cells) respectively as much IL-2 in the intestinal
mucosal lymphocytes (Fig. 4 (right), panel B). It induces
the differentiation of regulatory T cells, promotes T cell
growth and natural killer cell cytolytic activity, and medi-
ates activation induced cell death.
In comparison with LLE7BF_CD4 and LLOE7BF_CD4
groups, LLE7FBF_CD4 and LLOE7FBF_CD4 groups also
stimulated almost 1.78 time (59.0752 to 67.1248 vs.
32.1270 to 38.6730 spot-forming cells (SFC) per 104
cells) and 1.41 time (72.7879 to 82.2121 vs. 51.9708 to
57.8292 spot-forming cells (SFC) per 104 cells) more
IFN-γ in splenocytes respectively (Fig. 4 (left), panel C)
and almost 1.27 time (126.8711 to 140.9289 vs. 98.3404
to 111.6596 spot-forming cells (SFC) per 104 cells) and 1.31
time (147.7086 to 160.8914 vs. 109.6841 to 124.9159
spot-forming cells (SFC) per 104 cells) more IFN-γ in intes-
tinal mucosal lymphocytes respectively (Fig. 4 (right), panel
C). Also, in comparison with LLE7BF_CD8 and
LLOE7BF_CD8 groups, LLE7FBF_CD8 and LLOE7FBF_
CD8 groups also stimulated almost 1.11 time (113.3137 to
122.8863 vs. 99.9676 to 112.0324 spot-forming cells (SFC)
per 104 cells) and 1.25 time (133.7699 to 146.0301 vs.
108.2753 to 114.9247 spot-forming cells (SFC) per 104 cells)
more IFN-γ in splenocytes respectively (Fig. 4 (left), panel
C) and almost 1.07 time (250.5920 to 263.6080 vs. 229.6767
to 247.5233 spot-forming cells (SFC) per 104 cells) and 1.09
time (261.9172 to 282.4828 vs. 242.0938 to 253.7062
spot-forming cells (SFC) per 104 cells) more IFN-γ in intes-
tinal mucosal lymphocytes respectively (Fig. 4 (right), panel
C), which is a powerful activator of macrophages, inducer
of MHC I and MHC II expression, and indicator of Th1
responses.
To evaluate the E7-specific cytotoxic T lymphocyte
(CTL) responses, we performed lactate dehydrogenase
(LDH) activity assays using intestinal mucosal lympho-
cytes stimulated with 1 g/mL synthesized HPV-16 E749–
57 peptide which LLE7FBF. The LLOE7FBF mice group
indicated a significant cellular response compared to
Mohseni et al. BMC Biotechnology            (2019) 19:8 Page 6 of 13
Fig. 4 (See legend on next page.)
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LLE7BF and LLOE7BF groups at this ratio, with effec-
tor:TC-1 (30:1 ratio) (P = 0.0001). However, no signifi-
cant difference was observed in the CTL activity
between PBS and LLEV groups (P = 0.7263).
Challenge study
In tumor protection study, compared with LLE7BF
and LLOE7BF groups, LLE7FBF and LLOE7FBF
groups led to a significant delay in tumor growth and
an increased tumor protection on day 41 (median
tumor size of 3 and 1 cm3, respectively) (P = 0.0001).
In contrast, all LLEV mice groups grew tumors with
a median tumor size of 6 cm3.
In the tumor treatment study, LLE7FBF and
LLOE7FBF groups had better treatment effects on pro-
gression of tumor size in comparison with LLE7BF and
LLOE7BF groups, with a median tumor size of 2.9 and
1.1 cm3, respectively (P < 0.0001). However, LLEV mice
treatment groups had no significant inhibitions for
tumor growth, with a median tumor size of 5.9 cm3.
Finally, the median survival rate of the mice immu-
nized with LLE7BF, LLE7FBF, LLOE7BF, and LLOE7FBF
groups was 43, 61, 62, and 69% over 60, 66, 63, and 72
days after inoculation of the TC-1 tumor (P < 0.0001),
respectively, while that of the mice immunized with
LLEV group was 10% over 25 days (Fig. 5, left panel).
(See figure on previous page.)
Fig. 4 Panel a: The levels of E7-specific IgG and SIgA antibodies in serum (left) and vaginal discharges (right), respectively, on day 41; the sera and
vaginal discharge samples were tested by indirect ELISA using recombinant human papillomavirus type 16 protein E7 as the coating antigen. Goat-
anti-mouse IgG-H&L (HRP) antibody and Goat Anti-Mouse IgA alpha chain (HRP) were used as a secondary antibody. The absorbance of each
microwell was read on a spectrophotometer at 450 nm. Error bars represent the mean ± standard error value of each group (P < 0.001). Panels b and c:
Detection of E7-specific T-lymphocytes using an IL-2 (panel b) and IFN-γ (panel c) ELISPOT assay in the splenocytes (left) and intestinal mucosal
lymphocytes (right); female C57BL/6 mice were immunized orally with 109 CFU of Lactococcus lactis containing rE7 on days 1, 2, 3, 14, 15, 16, 29, 30,
and 31. In order to measure cytokine production from the cells, on day 41 (ten days after the last immunization), intestinal mucosal lymphocytes and
splenocytes were collected and stimulated with MHC class I - restricted peptides and MHC class II - restricted peptides (HPV-16 E749–57 and HPV-16
E730–67, respectively). Then, the level of E7-specific IFN-γ-producing CD8+ and CD4+ T cells and E7-specific IL-2-producing CD8+ and CD4+ T cells was
calculated via mouse IFN-γ and IL-2 ELISPOT kit, respectively. The diagram demonstrates the number of spots per 104 splenocytes and intestinal
mucosal lymphocytes after stimulation. The results are presented as mean ± SD (n 10). PBS (Control group); LLEV: Induced L. lactis harboring pNZ8123;
LLE7BF: Induced L. lactis harboring pNZ8123-HPV16-E7 produced through batch fermentation; LLE7FBF: Induced L. lactis harboring pNZ8123-HPV16-E7
produced through fed-batch fermentation; LLOE7BF: Induced L. lactis harboring pNZ8123-HPV16-optiE7 produced through batch fermentation; and
LLOE7FBF: Induced L. lactis harboring pNZ8123-HPV16-optiE7 produced through fed-batch fermentation
Fig. 5 Kaplan–Meier plots of survival probability in C57BL/6-vaccinated mice (left panel) and TC-1 tumor-bearing C57BL/6 mice treated with
recombinant strains (right panel); the data confirmed that immunization with L. lactis harboring pNZ8123-HPV16-optiE7 produced through fed-
batch fermentation via the oral route generated the most powerful tumor protection (P < 0.0001). The survival time of tumor-bearing mice was
considerably higher in the LLOE7FBF group. PBS (Control group); LLEV: Induced L. lactis harboring pNZ8123; LLE7BF: Induced L. lactis harboring
pNZ8123-HPV16-E7 produced through batch fermentation; LLE7FBF: Induced L. lactis harboring pNZ8123-HPV16-E7 produced through fed-batch
fermentation; LLOE7BF: Induced L. lactis harboring pNZ8123-HPV16-optiE7 produced through batch fermentation; and LLOE7FBF: Induced L. lactis
harboring pNZ8123-HPV16-optiE7 produced through fed-batch fermentation
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Also, the median survival rate of the animals immunized
with LLEV, LLE7BF, LLE7FBF, LLOE7BF, and LLOE7FBF
group was 10, 44, 67, 60, and 72% over 19, 53, 69, 63,
and 74 days respectively over 75 days after treatment (P
< 0.0001), respectively (Fig. 5, right panel).
Discussion
Advanced optimization can be done to attain higher
expression levels with the different expression condi-
tions. The optimization procedure was conducted given
the level of nisin, codon usage optimization, cell density
at induction time, and induction temperature in the
growth medium to obtain a higher level of rE7 expres-
sion in L. lactis [12].
It was found that growth conditions in static flasks
cannot be simply controlled; hence, large batch-to-batch
variations may happen [6]. Production and recombinant
protein expression in a fermenter allows key variables
such as temperature, pH, and nutrient supply to be
regulated. Considering that culture optimization is an
efficient way to enhancing the overall recombinant pro-
tein yield in L. lactis, we further investigated the influ-
ence of culture condition in improving rE7 yields in L.
lactis NZ9000. We observed that production in a fer-
menter under controlled pH conditions resulted in bet-
ter glucose uptake and enhanced the productivity of the
culture when compared to static flask cultures. The re-
sults obtained from the optimization study of the batch
fermentation under various glucose concentrations were
in accordance with our previous studies, showing higher
efficiency in the production of rE7 protein and biomass
in the NZ9000 strains [12].
Despite approximately 22 years of laboratory applica-
tion of the NICE expression system, we did not find any
publications explaining the fed-batch production of
recombinant L. lactis NZ9000 harboring HPV-16 E7
oncogene. We also investigated the positive effect of
fed-batch fermentation on overproduction of rE7 protein
in both NZ9000 recombinants. In order to improve the
secretion of rE7 oncoprotein, the concentrated nutrients
were fed stepwise to investigate the effects of fed-batch
fermentations using different feeding agents. This ex-
perimental design enabled us to discover the effect of
glucose and yeast extract limitation on cell growth and
rE7 production. During the course of fed-batch fermen-
tation, biomass increased rapidly while the growth of the
microorganisms entered the logarithmic phase, where
the lag time of bacterial growth was shorter than that in
the batch culture.
From a kinetic point of view, it can be noted that rE7
expression improved rapidly in the first period in parallel
with the rapid rise in biomass and the maximum pH
drop developed in the culture. On the other hand, from
the ~ 7 h of fermentation, rE7 expression began to
decline in combination with the reduction in both the
biomass and pH drop rates. This suggested that the rE7
was produced in a pH dependent manner in this culture.
It has frequently been reported that accumulation of lac-
tic acid in the medium inhibits fermentation, resulting
in lower protein levels [18]. Also, after 30 h of fermenta-
tion, recombinants of L. lactis producing rE7 protein lost
their ability to recover the acidic condition at the end of
fermentation.
The second fed-batch fermentation was performed to
further improve rE7 production. Surprisingly, in the
second fed-batch experiment, a profile different from
the first fermentation profile was obtained. We con-
cluded that feeding yeast extract (nitrogen source) in
M17 medium supplemented with glucose reduced the
carbon source consumption, thus contributing to accu-
mulation of glucose in the medium culminating in slow
reduction of pH after 20 h of incubation along with the
rapid rise in the biomass and rE7 productions. This
result suggested that yeast extract provides both a com-
paratively larger amount of free amino acids and short
peptides as well as more growth factors compared to
other protein hydrolysates [19–21].
These results confirmed that the biomass and rE7 con-
centrations obtained at the end of the first and third
fed-batch culture were only slightly higher than in the
batch culture using the same fermenter. It was observed
that neither additional glucose supplementation (pro-
file 1) nor glucose plus yeast extract (profile 3) signifi-
cantly improved the biomass and rE7 production by L.
lactis due to toxicity of excess lactic acid accumulated in
the acidic environment. This effect was even more pro-
nounced in the profile 1 due to its high level of lactic
acid. In contrast, high levels of protein production were
achieved in the second fed-batch profile. It was seen that
yeast extract feeding strategy was an effective way for
improving rE7 production in L. lactis, confirming the in-
teractions between the nitrogen source and GM17
medium. From a practical point of view, the fed-batch
culture (profile 2) revealed 1.98- and 1.92-fold rise in the
cell dry weight of optiE7 and E7 compared with the
batch culture (Fig. 3 (right), panel B). Also, the positive
expression rates of rE7 protein significantly improved in
both recombinant strains (2.09- and 1.48-fold growths)
as compared with the batch experiments (Fig. 3 (right),
panel A). Further, the fed-batch fermentation time was
shorter than that of batch fermentation.
In this study, the ability of L. lactis recombinants harbor-
ing optiE7 and E7 producing rE7 during the batch and
fed-batch fermentation was assessed by determining the
presence of antigen-specific serum IgG and antigen-specific
vaginal SIgA antibodies. Taken together, our results suggest
that mice vaccinated orally with L. lactis expressing rE7
after prime-boost immunization can experience significant
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serum IgG levels and gain strong immunogenicity. It also
induces significant mucosal immune responses which may
contribute to protection against virus infection.
In comparison with LLE7BF and LLOE7BF groups,
LLE7FBF and LLOE7FBF groups provoked more E7-spe-
cific IFN-γ-secreting CD8+ T cell within the spleen and in-
testinal cells stimulated with HPV-16 E749–57 peptide
(MHC class I epitope). In contrast, compared with
LLE7BF and LLOE7BF groups, LLE7FBF and LLOE7FBF
groups stimulated more E7-specific Il-2-secreting CD4+ T
cells within the spleen and intestinal cells stimulated with
HPV-16 E730–67 peptide (MHC class II epitope). These
outcomes imply that LLE7FBF and LLOE7FBF mice
groups induced potent Th1 responses, which are neces-
sary for tumor regression and considerable E7-specific
antibody immune responses. Also, the results from tumor
challenge revealed that oral administration of L. lactis
expressing rE7 elicited antitumor effects against tumors in
C57/BL6 mice.
Overall, expression of recombinant E7 in L. lactis
and the observed immune response after oral immu-
nizations are a first step towards developing an ef-
fective preparation for immunizing HPV-16-positive
patients.
Conclusions
The two major contributions of this study have been
improving a suitable strategy for producing high concen-
trations of biomass and rE7 through batch and fed-batch
fermentation and assessing the protective and thera-
peutic immune responses induced by recombinant L.
lactis harboring E7 protein against HPV-16 Infection in
C57BL/6 Mice. We conclude that fed-batch strategy
reported in this paper can offer a significant incentive
for large-scale production of recombinant E7 protein.
Meanwhile, our results confirmed that both humoral
and cellular immune responses could be elicited upon
oral administration of recombinant L. lactis in
C57BL/6 mice. Overall, the strategy used in this study
may offer useful and cost-effective insights into devel-
oping a new generation of HPV therapeutic vaccines.
However, further studies are required to assess the
efficacy and safety of this recombinant construct in a
double-blind, placebo controlled study of patients
with cervical cancer.
Materials and methods
Bacterial strains, mice growth conditions, and TC-1 cell
lines
The strains of Lactococcus lactis subsp. cremoris NZ9000
(pepN::nisRK; commonly used host of the NICE system)
and E. coli MC1061 (an intermediate host for propagation
of shuttle vector) were purchased from MoBiTec com-
pany (MoBiTec, Goettingen, Germany). Also, E. coli
JM107 (host strain for propagation of T-vectors) was pur-
chased from Invitrogen company (Invitrogen, Carlsbad,
CA, USA). L. lactis NZ9000 was cultured on M17
medium (Merck, USA) containing glucose 0.5% at 30 °C.
On the other hand, E. coli strains were cultured on Luria
Bertani (LB) at 37 °C.
Specific pathogen-free (SPF) female 6- to 8-week-old
C57BL/6 mice were purchased from Pasteur Institute of
Iran (Tehran, IRAN). The mice were housed in appro-
priate conventional animal care facilities in the animal
house of Iran University of Medical Sciences under
standard conditions.
TC-1 cell line was donated by Prof. Hossein Keyvani.
TC-1 cells were generated by co-transformation of
C57BL/6 mouse lung epithelial cells with HPV-16 E6
and E7 oncogenes and the human ras oncogene. TC-1
cells were cultured in RPMI-1640 medium FCS 10%,
penicillin 50 U/mL, streptomycin 50 g/mL, and G418
0.4 mg/mL incubated at 37 °C in CO2 10%.
Construction of a L. lactis expression vector
Native and codon-optimized DNA fragments from the
HPV-16 genome spanning nucleotides 7604 to 7900 were
cloned into the pTZ57R/T (TA cloning vector, ampicillin
resistant) and pMD17 (T-cloning vector; lacZ; Ampr)
vector, respectively. The coding regions of recom-
binant pTZ57R plasmid were PCR amplified with
primers 5′-GCCGGCCATGGAGATACACCTACATT-3′
and 5′-GAGCTCTGGTTTCTGAGAACAG-3′. Also, the
coding regions of recombinant pMD17 plasmid were PCR
amplified with 5′- GCCGGCCATGGTGATACTCCAAC-3′
and 5′-GAGCTCTGGTTTTTGTGAACAAATTG -3′.
The underlines represent the NaeI and SacI sites, respect-
ively. Both PCR products were digested with NaeI and SacI
and cloned into pNZ8123 shuttle vector (repA and repC
replication elements, SPusp45 signal sequence, nisA-pro-
moter) downstream of the secretion of signal peptide
SPusp45 (signal sequence of the lactococcal major secreted
protein Usp45) in-frame between the Pnis and termin-
ator (MoBiTec, Germany) cut with the same enzyme,
creating pNZ8123-HPV16-E7 and pNZ8123-HPV16-
optiE7 plasmids. They were subsequently added to
chemically competent E. coli MC1061 cells [22]. The
bacteria were plated onto Luria–Bertani plates contain-
ing chloramphenicol (10 μg/mL) and streptomycin
(100 μg/mL). The pNZ8123-HPV16-E7 and
pNZ8123-HPV16-optiE7 vectors were transferred into
Electrocompetent NZ9000 by electroporation using a
Gene Pulser apparatus (Bio-Rad Laboratories, Inc., CA,
USA) following the MoBiTec’s instructions (MoBiTec,
Germany). GM17 agar supplemented with chloram-
phenicol was utilized for screening the recombinant
strains. The integrity of both vectors was checked by
DNA sequencing (Bioneer, Korea). Also, the expression
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pNZ8123 vector without insert was electro-transformed
into the NZ9000 competent cells as a negative control
strain.
In silico analysis of HPV-16 E7
The physiochemical parameters of HPV-16 E7 protein
were calculated by ProtParam tool of ExPASy (http://
web.expasy.org/protparam/). The potential secretory
signal peptide (SigP) was predicted based on SignalP
v4.1 (http://www.cbs.dtu.dk/services/SignalP/) with the
D-cutoff value of 0.45. In order to develop the protein
tertiary structure homology modeling, 3D structure
models of recombinant HPV-16 E7 sequences were
developed using an automated mode of SWISS-MODEL
protein structure homology modeling server (https://
swissmodel.expasy.org/).
Protein expression
Recombinant strains (NZ9000 containing pNZ8123-
HPV16-optiE7 or pNZ8123-HPV16-E7) were induced by
various concentrations of nisin (1, 5, 10, 15, and 20 ng/mL)
at different OD600 densities (0.5, 0.6, 0.7, and 0.8 nm) for 8
h at various culture temperatures (20 and 30 °C). The
supernatant (extracellular fraction) was collected through
centrifugation (12,000 rpm for 10min). The proteins were
separated via SDS polyacrylamide gel 12% electrophoresis
at 60 V for 180min. The recombinant protein was trans-
ferred to the PVDF membrane using a semi-dry blotter
(Transblot semi-dry Transfer Cell; Bio-Rad) and Western
blot was performed as described previously [8, 23]. Cell
Biolabs’ HPV-16 E7 Oncoprotein ELISA Kit was used for
quantification of extracellular proteins according to the
manufacturer’s recommendation (Cell Biolabs, Inc., USA).
Batch and fed-batch fermentation of recombinant
NZ9000 strains
Batch and fed-batch fermentation was performed in a
homemade 100-L fermenter equipped with a
temperature-control system, a pH meter, dissolved oxygen
(DO) sensor, temperature electrode, and magnetic stirrer.
The fermenter was inoculated with 50mL of an overnight
culture of each recombinant NZ9000 in M17 broth and
incubated at 20 °C for 40 h with varying initial concentra-
tions of glucose (25, 50, 75, and 100 g/L). The cultures in
the log phase (OD600 = 0.6 ± 0.1) were induced with nisin
(15 and 10 ng/mL final concentration for optiE7 and E7
respectively).
Three fed-batch experiments with various feeding pro-
files (after 20 h of batch culture) were examined in order
to improve the protein yield and to maximize the bio-
mass production. The feeding solutions used for the
fed-batch culture contained the following formula: con-
centrated glucose (450 g/L) (fermentation 1), GM17
medium supplemented with yeast extract 0.5% (w/v)
(fermentation 2), and mixture of glucose (450 g/L) plus
GM17 medium supplemented with yeast extract 0.5%
(w/v) (fermentation 3). The pH value was automatically
regulated within the range of 6.5–7 by adding NaOH 4
N solution using a peristaltic pump, where a slow agita-
tion (100 rpm) was maintained to keep the fermentation
broth homogeneous. The samples were taken aseptically
every 5 h at regular time intervals. The rE7 productions
were compared to evaluate the process efficiency of dif-
ferent fermentation modes. The biomass for each sample
was calculated by the culture’s optical density at 600 nm
(OD600). The optical density was calibrated against the
dry cell weight (DCW; 1 OD600 corresponded to 0.38 g/
L DCW). The numbers of viable cell counts (CFU/mL)
were determined by serial dilution and plate counts.
Immunization of C57BL/6 mice and CTL assays
Six groups of female C57BL/6 mice (n = 10/group) were
selected in this study. The mice group consisted of
Group 1- PBS; Group 2- LLEV: Induced L. lactis con-
taining pNZ8123; Group 3- LLE7BF: Induced L. lactis
containing pNZ8123-HPV16-E7 produced through
batch fermentation; Group 4- LLE7FBF: Induced L.
lactis containing pNZ8123-HPV16-E7 produced through
fed-batch fermentation; Group 5- LLOE7BF: Induced L.
lactis containing pNZ8123-HPV16-optiE7 produced
through batch fermentation; and Group 6- LLOE7FBF:
Induced L. lactis containing pNZ8123-HPV16-optiE7
produced through fed-batch fermentation.
Four groups were immunized orally with 100 μl of PBS
composed of 1 × 109 CFU/mL of each induced strain
expressing recombinant E7 on days 1, 2, and 3. Also,
two groups (n = 10/group) were immunized orally with
100 μl of PBS where 1 × 109 CFU/mL of the recombinant
strain containing empty shuttle vector served as control
groups. All groups also received a second immunization
on days 14, 15, and 16 with 100 μl of emulsion, plus a
third immunization on days 29, 30, and 31. All experi-
mental procedures were approved by the Institutional
Animal Care and Use Committee of Iran University of
Medical Sciences (96–03–30-29,914).
Indirect ELISA, ELISPOT, and CTL assays
The blood collected from the tail vein of each group of
mice on days 1, 29, and 41 were centrifuged at 4000 rpm
for 10min, and the separated sera were aliquoted for
detecting specific antibodies. Mice were anesthetized by
an ip injection containing xylazine and ketamine (0.40
mL for 10 kg of weight, Cheminova de Mexico, SA de
CV). The vaginal discharge samples were collected from
each anesthetized mice with 100 μL of PBS on days 1,
29, and 41. Also, on day 41 all mice were sacrificed
(under 75% CO2/25% O2 anesthesia), after which the in-
testinal mucosal lymphocytes and splenocytes were
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isolated from immunized mice according to the protocol
recommended by Reißig et al. [24] and BD Bioscience,
respectively.
Indirect ELISA following a standard protocol was
employed to determine the specific serum IgG and
secretory IgA (SIgA) in vaginal discharges. Specifically,
polyvinylchloride 96-well plates were coated with recom-
binant human papillomavirus type 16 Protein E7
(MBS1264011; MyBioSource, San Diego, CA, USA) at
10 μg/mL in carbonate-bicarbonate buffer (pH 9.6) and in-
cubated overnight at 4 °C. The plates were subsequently
blocked, washed, and incubated individually with the
two-fold diluted sera and one-fold diluted vaginal fluids
for 1 h at 37 °C. They were then washed and blotted in
100 μL of goat-anti-mouse IgG-H&L (HRP) antibody
(ab6789; Abcam, Canada; 1:1000 dilution) and goat
Anti-Mouse IgA alpha chain (HRP) (ab97235; Abcam,
Canada; 1:1000 dilution) at room temperature for 1 h.
Next, the color was created with 3,3′,5,5′,-tetramethyl-
benzidine (TMB) for 10 min at 37 °C. H2SO4 (2M)
(100 μl/well) was used to stop the reaction. The absorb-
ance of each well was recorded on a spectrophotometer
at OD = 450 nm.
To determine cytokine production from the cells, intes-
tinal mucosal lymphocytes and splenocytes were mixed
and stimulated with 1mL of complete medium containing
10 μg/mL of major histocompatibility complex (MHC)
class I - restricted peptides and major histocompatibility
complex (MHC) class II - restricted peptides (HPV-16
E749–57 and HPV-16 E730–67, respectively). Afterwards, the
number of E7-specific IFN-γ-producing CD8+ and CD4+
T cells and E7-specific IL-2-producing CD8+ and CD4+ T
cells were measured using mouse IFN-γ ELISPOT kit and
mouse IL-2 mouse ELISPOT kit, respectively, according
to the manufacturer’s instructions (R&D Systems, Inc.,
Minneapolis, MN). The results were quantified by calcu-
lating the number of spot forming cells (SFC) per number
of cells added to the well.
In order to determine cytotoxic activity, 10 days after
the last immunization (day 41), the isolated intestinal
mucosal lymphocytes were stimulated in vitro, with 1 g/
mL of synthesized HPV-16 E749–57 peptide in 1 mL of
RPMI 1640 supplemented with FCS 10% at 37 °C under
CO2 5%. After 5 days, the viable intestinal mucosal
lymphocytes were collected and used as effector cells,
while TC-1 cells were used as target cells. The lactate
dehydrogenase (LDH) activity kit (CytoTox 96® Non-
Radioactive Cytotoxicity Assay, Promega, Madison,
USA) was utilized to measure the effector cells against
TC-1 (target cells) at ratios of 30:1 according to the
manufacturer’s instructions.
Tumor protection and tumor treatment experiments
In the tumor protection experiments, three C57BL/6
mice group (n = 10/group) received 109 CFU recombin-
ant L. lactis NZ9000 containing pNZ8123 with and with-
out HPV-16 E7 on days 1, 2, 3, 14, 15, 16, 29, 30, and 31
via the oral route. On day 41, all mice were challenged
with 105 TC-1 tumor cells subcutaneously in the left
rear flank.
In the tumor treatment experiments, initially, three
C57BL/6 mice groups (n = 10/group) were injected (sub-
cutaneous) with 104 TC-1 tumor cells into the left rear
flank. The tumor growth was measured using a caliper.
When tumors were 4–6 mm in the mean diameter, all
mice were orally administered as described above.
The tumors were measured with calipers and the vol-
ume of the tumor was estimated as: (length × width2)/2.
For survival analysis, the mice were considered as dead
when the tumor reached 1000mm3. When the tumor
size of the immunized mice exceeded 1000mm3, the
mice were sacrificed and dissected.
Statistical analyses
Each independent experiment was conducted in tripli-
cate. All data points have been represented by mean,
with the 95% confidence interval (CI) of difference. The
differences between means of recombinant E7 and
biomass productions in batch and fed-batch fermenta-
tions and comparison of different immunization sched-
ules were captured through analysis of variance (t-test)
using the MedCalc software (version 17.6; MedCalc Soft-
ware, Mariakerke, Belgium) [25]. P-value less than 0.01 was
considered statistically significant. Also, the survival per-
centages were analyzed using Kaplan-Meier (KM) methods.
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